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INTRODUCTION
Interstitial lung disease (ILD) relatively often develops in
patients with connective tissue diseases, such as rheumatoid
arthritis (RA), polymyositis-dermatomyositis, progressive
systemic sclerosis, and mixed connective tissue disease. The
prevalence of ILD in patients with RA has been variably
reported according to the method of assessment. In radio-
graphic studies, the reported incidence of ILD has varied from
about 1.6 to 4.5% (1). However, up to 40% of patients who
were evaluated with pulmonary function tests demonstrated
abnormalities of diffusing capacity (2).
ILD associated with RA may be slowly progressive or relent-
lessly fatal. Traditionally, corticosteroids have been the main-
stay in the treatment of these patients, but their effect is gen-
erally limited and may be temporary. Although there have
been some anecdotal reports on the efficacies of cytotoxic
agents such as methotrexate, D-penicillamine, azathioprine,
and cyclophosphamide (3-6), no convincing study has been
established for these agents. So far, a limited information has
been available for cyclosporine trial in ILD associated with
RA. We describe a 49-yr-old female with RA and progres-
sive ILD refractory to corticosteroid and cyclophosphamide
who was effectively treated with cyclosporine.
CASE REPORT
In March 1999, a 49-yr-old woman presented with a 1-yr
history of polyarthralgia and shortness of breath on exertion.
She did not smoke and had no past history of environmental
toxin exposure. There was no medical history of photosensi-
tivity, oral ulcer, alopecia, and Raynaud phenomenon. On
physical examination, inspiratory crackles were heard on the
both lower lung fields, and heart sounds were normal. The
joint swelling and tenderness were noted on the small joints
of both hands, right elbow, right first metatarsophalangeal
joint, and left third metatarsophalangeal joint. Laboratory
studies at this time showed a hemoglobin level of 11.3 g/dL
and a white blood cell count of 5,200/ L. The erythrocyte
sedimentation rate was 50 mm/hr. The C-reactive protein
was not increased. The rheumatoid factor was 340 IU/mL
and the antinuclear antibody titer was 1:640 with a speckled
pattern. The anti-extractable nuclear antigen and anti-dou-
ble-stranded DNA antibodies were absent. The complement
level was normal. There were no specific abnormalities on
other chemistry profiles.
A chest radiograph revealed bibasilar interstitial infiltrates
(Fig. 1A). High resolution computerized tomography (HRCT)
of the chest showed interstitial fibrosis, and ground glass
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Successful Treatment of Progressive Rheumatoid Interstitial Lung
Disease With Cyclosporine
: A Case Report
Treatment of interstitial lung disease (ILD) in rheumatoid arthritis (RA) has been
controversial. Although there have been several anecdotal reports on the effica-
cies of corticosteroids or cytotoxic agents such as methotrexate, cyclophos-
phamide, azathioprine, and D-penicillamine for the treatment of ILD associated
with RA, no controlled studies have been performed. To date, corticosteroids
have been a central agent for the treatment of this disease, but their effects are
partial and temporary in most cases. In addition, the adverse effects of these
agents are considerable. On the other hand, limited information is available on
the cyclosporine use in ILD associated with RA. We describe a 49-yr old female
patient with RA and ILD that had initially responded to high dose prednisolone
and cyclophosphamide intravenous pulse therapy, and the lung disease was
aggravated with the tapering of prednisolone. After 10 months of follow-up loss,
the patient was successfully treated with low dose cyclosporine without high
dose corticosteroids.
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opacities suggesting active inflammation on the both lower
lung fields. A pulmonary function test revealed a mild restric-
tive pattern with forced vital capacity (FVC) of 78% of pre-
dicted. The carbon monoxide diffusing capacity was 46% of
predicted. Although juxta-articular osteoporosis in the plain
radiographs was noted around proximal interphalangeal joints
of both hands, right wrist, and right elbow, bony erosions
were absent.
A diagnosis of RA with active ILD was established. Her
initial medications included prednisolone 1 mg/kg daily, hy-
droxychloroquine 200 mg b.i.d. and nabumetone 500 mg
b.i.d. Monthly cyclophosphamide intravenous (IV) pulse ther-
apy with a dose of 600 mg/m2 was started. Three weeks later,
dyspnea and polyarthralgia improved. The pulmonary func-
tion test was also improved with FVC of 85% of predicted
and diffusing capacity of 56% of predicted. The dosage of
prednisolone was gradually tapered to 7.5 mg over the next
4 months. Monthly cyclophosphamide IV pulse therapy was
continued.
In September 1999, she complained of a shortness of breath
of a greater severity. At that time, pulmonary function was
aggravated with FVC 72% of predicted and diffusing capac-
ity of 50%. HRCT showed progressive basal interstitial infil-
trates and increased ground glass opacities compared with
Fig. 1. A 49-yr-old woman presented with a 1-yr history of polyarth-
ralgia and shortness of breath on exertion. (A) posteroanterior (PA)
chest radiograph shows medium reticular pattern (small arrow) of
interstitial lung disease (ILD) and patchy ground glass opacities
(large arrow) in both lower lung fields with predominant bibasilar
and subpleural distribution. (B) PA chest radiograph, 16 months
later, shows a progression of ILD with increased ground glass
opacities (small arrow) and consolidation (large arrow) in both
lower lung fields and left upper lobe. (C) PA chest radiograph after
cyclosporine administration shows improvement of ILD with resid-
ual fine reticular pattern and patchy ground glass opacities (small
arrow) in left lower lung.
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the findings in March 1999. Cyclosporine 3.6 mg/kg (200
mg) daily was prescribed, and prednisolone was increased to
20 mg daily, but she did not take this medication and was
lost from follow-up. During this period she had not taken
any medical treatment except herb medications.
In July 2000, she was admitted again with complaints of
shortness of breath on minimal exertion and severe polyarthral-
gia. Physical examination revealed inspiratory crackles and
coarse breath sounds on both lower lung fields. There were
swelling and tenderness on the multiple joints such as small
joints of both hands, both elbows, both knee joints, and right
ankle. On laboratory studies, a white blood cell count was
10,000/ L and a hemoglobin level was 11 g/dL. Arterial
blood gas analysis without O2 supplementation showed a
PaO2 of 54.1 mmHg, PaCO2 of 27.6 mmHg, and O2 satura-
tion of 90.1%. The lung infiltrates on the chest radiograph
(Fig. 1B) and HRCT (Fig. 2) were more aggravated with an
extension to left upper lobe. The pulmonary function was also
aggravated with FVC of 54% of predicted and diffusing
capacity of 37% of predicted. A transbronchial lung biopsy
showed interstitial fibrosis and mononuclear cell infiltrates,
which were compatible with interstitial pneumonitis. Bac-
terial cultures grew normal flora of the upper respiratory
tract. Cultures for fungus and mycobacteria were negative.
She was considered to have as advanced ILD with active
inflammation in association with RA. Daily cyclosporine
3.6 mg/kg (200 mg), prednisolone 5 mg, and celecoxib 200
mg were started. Within 4 weeks, her breathlessness and
joint symptoms markedly improved. The pulmonary function
test revealed FVC of 69% of predicted and diffusing capaci-
ty of 39% of predicted. Serum trough level of cyclosporine
was 119 ng/mL. In December 2000, her shortness of breath
further improved and stabilized. Chest radiograph (Fig. 1C)
and HRCT at this time showed markedly reduced pulmonary
infiltrates. The dosage of cyclosporine could be reduced to
2.7 mg/kg (150 mg) daily. Mild hypertension which was the
only side effect of cyclosporine, was controlled with amlodip-
ine. In January 2001, she was free of joint symptoms, and
only had mild dyspnea on exertion.
DISCUSSION
The clinical course of ILD associated with RA is variable.
Whereas some patients take gradually progressive clinical
course (7), other patients run a rapidly progressive course
that can be fatal within several months (2). Spontaneous
remission for this disease has been rarely reported (8). The
clinical presentation and the pathologic findings of ILD in
RA are known to be very similar to those of idiopathic pul-
monary fibrosis, and the therapeutic modalities for these two
diseases are not much different. Although some RA patients
with progressive ILD may respond to aggressive immuno-
suppressive therapy, treatment for this disease still remains
controversial.
To date, the corticosteroids have been the central agent for
the treatment of progressive ILD in RA. However, the favor-
able response rate to these agents has been reported less than
40%, and documentation of sustained effect is even rare (2,
9, 10). Although there have been several anecdotal reports
for the efficacies of cytotoxic agents such as methotrexate,
azathioprine, D-penicillamine, and cyclophosphamide in
patients with RA and progressive ILD, few controlled studies
have demonstrated the sustained effects of these agents (2).
The efficacy of cyclosporine for the treatment of RA has
been proven (11-13). Even if there have been a few reports
for the successful cyclosporine use in progressive ILD or acute
interstitial pneumonitis in association with RA, the available
Fig. 2. (A) HRCT at the level of the carina shows consolidation (large arrow) in the posterior segment of left upper lobe and superior seg-
ment of left lower lobe. Interlobular septal thickening (small arrows) and subpleural traction bronchiolectasis (arrowhead) are noted in
anterior segment of left upper lobe. (B) HRCT at left atrium level shows ground glass opacity (small arrows) and consolidation (large
arrow). Traction bronchiectasis (thin arrow), thickening of major fissure, and irregular interlobular septal thickening (arrowhead) are pre-
sent in the both lower lobe.
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information is still limited (14-17). Alegre et al. first described
the successful treatment of aggressive pulmonary fibrosis in
RA with cyclosporine (14). In contrast to our case, that patient
had symptoms for less than one month before treatment, and
had not been treated with any other immunosuppressive
agents. In addition they used high dose prednisone and high-
er dose cyclosporine than in our case. Puttick et al. reported
the effect of cyclosporine in a patient with long-standing RA
and progressive ILD that had been refractory to corticosteroids
and cytotoxic agents such as chlorambucil and oral cyclophos-
phamide. They used similar dose of cyclosporine and higher
dose of prednisolone, compared with our case (15).
Our patient had initially responded to high dose pred-
nisolone and cyclophophamide IV pulse therapy. However,
her lung disease was aggravated with the tapering of pred-
nisolone for 6 months. After 10 months of follow-up loss,
ILD was much more aggravated. At that time, she was treat-
ed with low doses of cyclosporine and prednisolone (5 mg/day).
Despite subjective symptoms, her pulmonary function such
as forced vital capacity, and radiographic pulmonary infiltrates
have much improved with these agents, the diffusing capacity
did not change. This may reflect the ventilation-perfusion
mismatch in irreversibly damaged lung lesions. Most patients
in the literature who showed the effectiveness of cyclosporine,
including our case, the improvement exhibited within one
month. Because other patients than ours had used cyclosporine
together with higher dose of corticosteroids, it is not certain
whether the therapeutic improvement was due to cyclosporine
or to corticosteroids. On the other hand, as the spontaneous
remission is extremely rare in progressive ILD associated with
RA, the improvement of the lung disease in the present case
was mostly considered to be the effect of cyclosporine.
Cyclosporine, a complex fungal decapeptide, has highly
selective immunosuppressive properties. This agent appears
to reduce interleukin-2 synthesis by activated T-cell (18) and
to disrupt cytokine-dependent T lymphocyte-macrophage
interaction, and thus prevents fibroblast-mediated fibrosis
that is thought to be important in the pathogenesis of ILD
(2). Recently, Sekigawa et al. described 4 cases of steroid-resis-
tant autoimmune diseases who were effectively treated with
an extremely low dose of cyclosporine (1 mg/kg/day) (19). Due
to the limited information of cyclosporine in the treatment
of RA with ILD, the controlled studies are needed to clarify
whether cyclosporine is effective agent for the treatment of
ILD associated with RA, whether high dose corticosteroids
are required together with cyclosporine, and which dosage
of cyclosporine is optimal.
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